市場調查報告書

心臟麻痺治療市場:成長,趨勢,預測(2020∼2025)

Cardiac Arrest Treatment Market - Growth, Trends And Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 927865
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
心臟麻痺治療市場:成長,趨勢,預測(2020∼2025) Cardiac Arrest Treatment Market - Growth, Trends And Forecast (2020 - 2025)
出版日期: 2020年03月01日內容資訊: 英文 120 Pages
簡介

全球心臟麻痺治療市場預計在2020年∼2025年間將以4.8%的年複合成長率擴大。各種冠狀動脈性心臟病的盛行率的增加,心臟麻痺導致死亡的心肌病,老年人口的增加等要素,也提高有時效性的治療需求。

本報告提供心臟麻痺治療的世界市場調查,市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
    • 中風和冠狀動脈性心臟衰竭等心臟疾病的全球盛行率上升
    • 技術性與進步的產品的利用可能性償付方針
  • 阻礙因素
    • 經皮冠狀動脈介入治療等的低侵入性治療的採用
    • 高度的醫療保健基礎設施,熟練的專家,高額的治療方法的缺乏
  • 波特的五力分析

第5章 市場區隔

  • 各治療
    • 藥物
    • 醫療設備
  • 各流通管道
    • 醫院
    • 藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Koninklijke Philips NV
    • Boston Scientific Corporation
    • GE Healthcare
    • Abbott Laboratories
    • Novartis International AG
    • Johnson & Johnson
    • Pfizer Inc.
    • Amgen Inc
    • METsis Medikal
    • Medtronic plc

第7章 市場機會及未來趨勢

目錄
Product Code: 68216

The Cardiac Arrest Treatment Market studied was anticipated to grow with a CAGR of nearly 4.8% during the forecast period. The major factors driving the growth of the market are the increasing prevalence of various coronary heart diseases, cardiomyopathy which is leading to cardiac arrest deaths, favourable reimbursement initiatives and rise in geriatric population. For instance, according to Global Health And Wellness Report published in 2018, nearly 40% of the adult population in United States were diagnosed with a cardiovascular condition in the United States which directly resulted in higher demand for highly efficient, immediate treatment, and better technological advanced cardiovascular devices to save the life of the patients fueling the growth of the market throughout the forecasted period.

Key Market Trends

The Drug Segment is Expected to Hold the Largest Market Share in the Cardiac Arrest Treatment Market

  • The drugs segment is expected to witness the largest market share in the cardiac arrest treatment market during the forecast period. This dominance is due to the increased use of various drugs such as anti-cholinergics, beta blockers, vasopressors, and fibrinolytic drugs owing to the rise in prescriptions by the cardiologists.
  • Futhermore, anti-arrhythmic drugs are widely used by the most of patients for the treatment of potential arrhythmia and in the emergency period to save the person from heart failure or cardiac arrest. On the other hand, medical devices such as defibrillators and cardiac resynchronization therapy (CRT) are gaining attraction in the recent years and are anticipated to witness a significant growth in the forecast period due to rising awareness among the patients. Furthermore, the growth can be attributed to the rise in usage by the people who are expected to face cardiac arrest problem in the near future.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall cardiac arrest treatment market throughout the forecast period. The major factors attributing to the growth are a rise in the global prevalence of multiple cardiovascular indications like CAD, strokes and atrial fibrillation along with the rise in chronic diseases such as diabetes & obesity necessitating efficient cardiac arrest treatment. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases among which CAD was the major cause of death resulted in higher demand for better treatment technologies driving the market in the United States contributing to the outstanding share of revenue propelling the global cardiac arrest treatment market throughout the forecasted period.

Competitive Landscape

The cardiac arrest market is moderately competitive and consists of several major players. Few of the key players are developing the novel product and technologies to compete with the existing products while others are acquiring and partnering with the other companies trending in the market. For instance, in January 2017, Abbott acquired St. Jude Medical, expanded its medical device segment globally by adding breakthrough inventions of SJM to its existing product portfolio of cardiovascular devices such as the Quadra Allure MP CRT-P, used as cardiac resynchronization therapy in managing cardiac failure which is further expected to foster the global cardiac arrest market growth throughout the forecast period. Some of the companies which are currently dominating the market are Koninklijke Philips N.V, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, and Novartis AG.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Global Prevalence of Cardiac Disorders such as Strokes and Coronary Heart Failures
    • 4.2.2 Availability of Technologically Advanced Products and Reimbursement Policies
  • 4.3 Market Restraints
    • 4.3.1 Adoption of Minimally Invasive Procedures like Percutaneous Coronary Interventions
    • 4.3.2 Lack of Advanced Healthcare Infrastructure, Skilled Professionals and Highly Expensive Treatments
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Drugs
      • 5.1.1.1 Vasopressors
      • 5.1.1.2 Anti-arrhythmic Drugs
      • 5.1.1.3 Anticholinergic Drugs
      • 5.1.1.4 Antihypertensives
      • 5.1.1.5 Others
    • 5.1.2 Medical Devices
      • 5.1.2.1 Cardiac Resynchronization Therapy (CRT)
      • 5.1.2.2 Defibrillators
      • 5.1.2.3 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospitals
    • 5.2.2 Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United states
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Koninklijke Philips N.V
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 GE Healthcare
    • 6.1.4 Abbott Laboratories
    • 6.1.5 Novartis International AG
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Amgen Inc
    • 6.1.9 METsis Medikal
    • 6.1.10 Medtronic plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS